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Lipoprotein(a)- and low-density lipoprotein–derived choles-
terol in nephrotic syndrome: Impact on lipid-lowering therapy?
Background. Patients with nephrotic syndrome have the
highest lipoprotein(a) [Lp(a)] concentrations known. Lp(a) is
an low-density lipoprotein (LDL)-like particle consisting of
45% cholesterol. The usual methods to determine LDL choles-
terol do not distinguish between cholesterol derived from LDL
and Lp(a) and are thus the net result of cholesterol levels from
both lipoproteins. High Lp(a) concentrations therefore signif-
icantly contribute to the measured or calculated LDL choles-
terol levels. Since statins have no influence on Lp(a) levels, it can
be expected that the LDL cholesterol-lowering effect of statins
may be diminished in patients who have a pronounced eleva-
tion of Lp(a) levels accompanied by only moderate elevations
of LDL cholesterol.
Methods. We investigated 207 patients with nondiabetic
nephrotic syndrome in whom Lp(a) concentrations were strik-
ingly elevated when compared to 274 controls (60.4 ± 85.4 mg/
dL vs. 20.0 ± 32.8 mg/dL, P < 0.0001).
Results. According to National Kidney Foundation Dial-
ysis Outcomes Quality Initiative (K/DOQI) Clinical Prac-
tice Guidelines for Managing Dyslipidemias, almost 95% of
these patients are candidates for a therapeutic intervention to
lower LDL cholesterol. LDL cholesterol levels corrected for
Lp(a)-derived cholesterol, however, were 27 mg/dL lower than
uncorrected concentrations (compared to only 9 mg/dL in con-
trols). If Lp(a)-corrected levels instead of total LDL cholesterol
levels were used, 25.7% of patients with low-molecular-weight
(LMW) apolipoprotein(a) [apo(a)] isoforms were classified no
longer to be in need of LDL cholesterol-lowering therapeu-
tic intervention compared to only 2.3% of patients with high-
molecular-weight (HMW) apo(a) phenotypes (P < 0.00001).
This (“pseudo”) pharmacogenetic effect results in incorrect de-
termination of LDL cholesterol.
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Conclusion. Our observation has an impact on the indication
for, and assessment of efficacy of intervention. This potential
artifact should be investigated in ongoing large trials in renal
patients as well as in nonrenal African American subjects who
have on average markedly higher Lp(a) levels. In nonrenal Cau-
casian subjects with much lower Lp(a) concentrations, this issue
will be less relevant.
Lipoprotein(a) [Lp(a)] has two faces. On one side, it
is a lipoprotein which shows an independent effect on
atherogenesis [1, 2]. On the other hand, the particle is
very similar to low-density lipoprotein (LDL). It consists
of an LDL particle to which the glycoprotein apolipopro-
tein(a) [apo(a)] is attached. This apolipoprotein shows a
size polymorphism originating from a variable number
of kringle IV (K-IV) repeats at the apo(a) gene locus [3,
4]. This polymorphism [5] is the most important deter-
minant of Lp(a) levels which exhibit marked interindi-
vidual variation by more than 1000-fold. Individuals
expressing a low number of K-IV repeats [low-molecular-
weight (LMW) apo(a) phenotypes] show on average
markedly higher Lp(a) concentrations than those with
a high number of K-IV repeats [high-molecular-weight
(HMW) apo(a) phenotypes] who usually have low Lp(a)
concentrations. There exists strong evidence that both
LDL cholesterol and Lp(a) are risk factors for cardiovas-
cular disease in the general population [6]. One of the ma-
jor differences between both particles is the fact that LDL
cholesterol can be effectively lowered by the widely used
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins), while Lp(a) concentrations
are resistant to this treatment [7–13].
The usual methods to determine LDL cholesterol lev-
els, including the calculation by the Friedewald formula
do not distinguish between cholesterol derived from LDL
and Lp(a) and therefore represent the sum of cholesterol
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from both lipoproteins. Since Lp(a) consists of about 45%
cholesterol [14, 15], the LDL cholesterol fraction will be
overestimated when Lp(a) levels are very high. For in-
stance, if a person has an Lp(a) level of 200 mg/dL, his
or her LDL cholesterol fraction will be overestimated by
90 mg/dL. Since statins do not influence Lp(a) levels [7–
13], it can be expected that in those patients who have
strikingly elevated Lp(a) levels and only mild to moder-
ate elevation of LDL cholesterol the LDL cholesterol-
lowering effect of statins will be masked, in contrast to
patients with low Lp(a) levels. Moreover, since Lp(a)
concentrations are particularly elevated in patients with
small apo(a) isoforms, the LDL-lowering efficacy of
statins might depend on the apo(a) size polymorphism.
Lp(a) levels are significantly elevated in patients with
nephrotic syndrome [16–26]. In the present study we
investigated the Lp(a)-corrected LDL cholesterol con-
centrations in nephrotic patients. Based on the data we
discuss the impact of the genetically determined apo(a)
polymorphism on the response of measured LDL choles-
terol and the impact on the indication for, and assessment
of efficacy of intervention therapy.
METHODS
Patients
We included 207 consecutive patients with nephrotic
syndrome from the Department of Nephrology of the
University of Innsbruck (N = 155), the Munich Univer-
sity Hospital and some outpatient clinics in Bavaria (N =
37), and the Department of Nephrology at the Univer-
sity of Du¨sseldorf (N = 15) as recently described [26].
Patients were included in the study when they underwent
kidney biopsy and when they had at least one exact mea-
surement of 24-hour protein excretion (>3.5 g/24 hours)
and serum creatinine, if height and weight were available
and if a fasting blood sample had been collected. Patients
were carefully instructed for the 24-hour urine collec-
tion which was monitored by comparing the observed
and expected 24-hour creatinine excretion by urine. Pa-
tients with diabetic nephropathy were excluded from the
study. All patients were Caucasians and were not in need
of renal replacement therapy. Patients were compared to
274 age- and gender-matched controls of the same eth-
nic origin without renal impairment or liver disease who
were recruited in 1997 from one of the PROCAM study
centers [27]. For clinical characteristics of patients and
controls see Table 1.
Laboratory procedures
Serum and ethylenediaminetetraacetic acid (EDTA)
plasma were taken after a 12-hour overnight fast. After
low-speed centrifugation, samples were frozen and kept
at −80◦C prior to analysis [28]. We calculated the creati-
nine clearance using the formula of Cockcroft and Gault
Table 1. Characteristics of patients with nephrotic syndrome and
age- and gender-matched controlsa
Controls Nephrotic syndrome
(N = 274) (N = 207)
Age years 44.6 ± 12.4 43.5 ± 16.0
Gender females/males 97/177 76/131
Body mass index kg/m2 26.1 ± 3.7 25.1 ± 3.9c
Creatinine clearance 101 ± 27 [84, 97, 113] 73 ± 40 [40, 68, 98]b
mL/min
Creatinine mg/dL 0.99 ± 0.17 1.83 ± 1.38b
Urea mg/dL 31 ± 8 55 ± 35b
Proteinuria — 7.1 ± 3.6 [4.4, 6.0, 8.6]
g/24 hours/1.73 m2
Serum albumin g/dL 4.88 ± 0.47 3.01 ± 0.96b
Total protein g/dL 7.0 ± 0.4 5.9 ± 1.1b
aData are mean ± SD and [25th percentile, median, 75th percentile] where
appropriate.
bP < 0.001; cP < 0.01 for comparison with controls.
[29]. Measurement of lipids, serum albumin, Lp(a), and
apo(a) phenotyping were performed centrally in a single
laboratory to avoid interlaboratory differences in mea-
surements. Measurements were done in batches to avoid
a prolonged storage period before measurements. To-
tal cholesterol, high-density lipoprotein (HDL) choles-
terol, triglycerides as well as albumin (bromo-cresol
green method) were measured using kits from Roche
(Mannheim, Germany) [30]. Measurements were made
on microtiter plates as previously described [28]. LDL
cholesterol was calculated with the Friedewald formula
as follows:
LDL cholesterol = total cholesterol − HDL cholesterol
− (triglycerides/5)
The precipitation of apolipoprotein B (apoB)-
containing lipoproteins for the measurement of HDL
cholesterol in the supernatant results in an almost com-
plete precipitation of Lp(a) particles. Only 0.38 mg/dL of
Lp(a) particles on average remain in the supernatant (un-
published results). Thus, the Friedewald formula reveals
both the LDL- and Lp(a)-derived cholesterol. We there-
fore calculated the Lp(a)-corrected LDL cholesterol by a
modified version of the formula which considers that 45%
of Lp(a) consists of cholesterol [14, 15]. This value differs
from earlier studies which proposed 30% for correction
and was recently determined by different methods and
two independent study groups [14, 15]. This relative pro-
portion is further supported by the observation that the
lipid composition of LDL and LDL from Lp(a) is very
similar [31–33] and the fact that LDL consists of rather
50% than 30% cholesterol. The modified formula is as
follows:
Lp(a)-corrected LDL cholesterol
= total cholesterol − HDL cholesterol (triglycerides/5)
− [Lp(a) × 0.45]
Lp(a) quantification was performed as described
in detail [28] with a double-antibody enzyme-linked
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Table 2. Mean (±SD) plasma lipids and lipoprotein(a) [Lp(a)] in
patients with nephrotic syndrome and healthy controls
Nephrotic
Controls syndrome
N = 274 N = 207
Total cholesterol mg/dL 203 ± 42 302 ± 92a
Triglycerides mg/dL 136 ± 92 251 ± 174b
HDL cholesterol mg/dL 44.0 ± 12.6 43.7 ± 16.7
Total/HDL cholesterol ratio 4.9 ± 1.6 8.0 ± 4.5a
LDL cholesterol mg/dL 132 ± 37 208 ± 82a
Lp(a) mg/dL 20.0 ± 32.8 60.4 ± 85.4b
mean ± SD [25th percentile, [2.0, 6.4, 18.5] [9.6, 29.8, 81.1]
median, 75th percentile]
Lp(a)-derived LDL cholesterol 9.0 ± 14.7 27.2 ± 38.4b
mg/dL
Lp(a)-corrected LDL cholesterol 123 ± 39 181 ± 82a
mg/dL
Abbreviations are: HDL, high-density lipoprotein; LDL, low-density lipopro-
tein; Lp(a), lipoprotein(a).
aP < 0.0001 by t test for comparison between patients and controls.
bP < 0.0001 by Wilcoxon rank sum test for comparison between patients and
controls.
immunosorbent assay (ELISA) using an affinity-
purified polyclonal apo(a) antibody for coating and the
horseradish peroxidase-conjugated monoclonal 1A2 for
detection. An Lp(a)-positive serum from Technoclone
(Vienna, Austria) with the same apo(a) isoforms served
as standard throughout the study. Each sample was ana-
lyzed in duplicate, and intra- and interassay coefficients of
variation were 2.7% and 6%, respectively. Apo(a) pheno-
typing was performed by sodium dodecyl sulfate-agarose
gel electrophoresis (SDS agarose) under reducing condi-
tions as outlined [34].
Statistical procedures
Statistical analysis was performed with Statistical Pack-
age for the Social Sciences (SPSS, Inc., Chicago, IL,
USA) for Windows 11.0. Univariate comparisons of con-
tinuous variables between controls and nephrotic pa-
tients were done by unpaired t test or the nonparametric
Wilcoxon rank sum test in case of nonnormally dis-
tributed variables. Dichotomized variables were com-
pared using Pearson’s v 2 test or the likelihood ratio
v 2-test.
As in previous works from our and other groups [35–
37], we divided apo(a) phenotypes into two subgroups
according to the molecular weight of the smaller apo(a)
isoforms (discussed in [34]). The LMW group included all
subjects with at least one apo(a) isoform with 11 to 22 K-
IV repeats (usually about 25% of a population); the high
molecular weight (HMW) group comprised all subjects
having only isoforms with more than 22 K-IV repeats.
RESULTS
The patients with the nephrotic syndrome had marked
lipid abnormalities. They had strikingly elevated total and
LDL cholesterol levels as well as triglyceride concentra-
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Fig. 1. Lipoprotein(a) [Lp(a)]-derived low-density lipoprotein (LDL)
cholesterol in controls and patients with nephrotic syndrome strati-
fied by six apolipoprotein(a) [apo(a)] phenotype groups. Patients with
nephrotic syndrome had three times the amount of Lp(a)-derived LDL
cholesterol compared to controls (overall 27 mg/dL vs. 9 mg/dL). Pa-
tients with low-molecular-weight (LMW) compared to patients with
high-molecular weight (HMW) apo(a) phenotypes showed a signif-
icantly higher amount of Lp(a)-derived LDL cholesterol (47.8 ±
51.8 mg/dL vs. 15.7 ± 21.1 mg/dL, P < 0.001). K-IV is kringle IV.
tions while HDL cholesterol levels were unchanged when
compared to controls (Table 2). The total/HDL choles-
terol ratio was markedly elevated to 8.0 compared to
4.9 in controls. Patients with nephrotic syndrome showed
a tremendous elevation of Lp(a) serum concentrations.
The mean and median concentrations were three and five
times higher, respectively, when compared to controls
(mean 60.4 mg/dL vs. 20.0 mg/dL and median 29.8 mg/
dL vs. 6.4 mg/dL, respectively) (Table 2) [26]. About 30%
of the patients had Lp(a) levels above 70 mg/dL. This
could only be observed in 8.4% of the controls.
Since Lp(a) consists of 45% cholesterol, we expected
that a significant proportion of LDL cholesterol in
nephrotic patients was accounted for by Lp(a) particles.
We therefore corrected the LDL cholesterol levels de-
rived from the Friedewald formula by subtracting 45%
of the measured Lp(a) concentrations. These corrected
LDL cholesterol levels were only 9 mg/dL lower in con-
trols when compared to the uncorrected levels. In patients
with nephrotic syndrome, however, the difference was
more than 27 mg/dL (Table 2). The difference was three
times greater in patients with LMW compared to patients
with HMW apo(a) phenotypes (47.8 ± 51.8 mg/dL vs.
15.7 ± 21.1 mg/dL, P < 0.001) (Fig. 1). Forty-three
out of 74 patients (58%) with LMW apo(a) phenotypes
showed Lp(a)-corrected LDL cholesterol levels which
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Fig. 2. Low-density lipoprotein (LDL) cholesterol and lipopro-
tein(a) [Lp(a)]-corrected LDL cholesterol levels in patients with
low-molecular-weight (LMW) and high-molecular-weight (HMW)
apolipoprotein(a) [apo(a)] phenotypes. Only patients are presented
who showed at least 30 mg/dL difference between the two LDL choles-
terol levels. This was significantly less the case in patients with HMW
than in those with LMW apo(a) phenotypes (16% vs. 58%; P < 0.00001).
were at least 30 mg/dL lower than the uncorrected LDL
cholesterol levels. The frequency was significantly lower
in patients with HMW apo(a) phenotypes (21 out of
133 patients, 16%; P < 0.00001) (Fig. 2).
Finally, we considered how many of the investigated
patients would have to be considered for therapeutic in-
tervention based on the LDL cholesterol concentrations
according to the Adult Treatment Panel III (ATP III)
guidelines [38] and the recommendation of the National
Kidney Foundation [39]. Both recommendations define
an LDL cholesterol target of <100 mg/dL. Almost all
of the patients (94.7%) would have needed intervention
irrespective of the apo(a) phenotype groups (95.9%
and 93.9% for patients with LMW and HMW apo(a)
phenotypes, respectively). When Lp(a)-corrected LDL
cholesterol levels were used the proportion of patients
requiring intervention was much lower for patients with
LMW apo(a) phenotypes (70.3%) but remained almost
unchanged for patients with HMW apo(a) phenotypes
(91.7%). Twenty-two of the total patient group (10.6%)
changed from the group matching the intervention crite-
ria (LDL cholesterol level ≥100 mg/dL) to the one failing
to match the criteria (corrected LDL cholesterol below
100 mg/dL). This was seen 11 times more frequently in
Table 3. Frequency of patients with nephrotic syndrome as well as
dialysis patients treated by hemodialysis or continuous ambulatory
peritoneal dialysis (CAPD) who have to be considered for therapeutic
intervention based on the Adult Treatment Panel III (ATP III)
guidelines [38] and the recommendation of the National Kidney
Foundation [39]
Apo(a) phenotypes
All LMW HMW
Nephrotic syndrome (N = 207)
Based on LDL cholesterol % 94.7 95.9 93.9
Based on Lp(a)-corrected 84.1 70.3 91.7
LDL cholesterol %
Frequency difference % 10.6 25.6 2.2
CAPD (N = 168)a
Based on LDL cholesterol % 86.3 84.4 87.0
Based on Lp(a)-corrected 78.0 62.2 83.7
LDL cholesterol %
Frequency difference % 8.3 22.2 3.3
Hemodialysis (N = 534)a
Based on LDL cholesterol % 60.9 59.9 61.3
Based on Lp(a)-corrected 49.7 44.5 51.5
LDL cholesterol %
Frequency difference % 11.2 15.4 9.8
Abbreviations are: Apo(a), apolipoprotein(a); LMW, low molecular weight;
HMW, high molecular weight; LDL, low-density lipoprotein; Lp(a), lipopro-
tein(a).
aPatients from the previous study [40].
patients with LMW than in those with HMW apo(a) phe-
notypes (25.6% vs. 2.2%, P < 0.00001) (Table 3) (Fig. 3).
We also calculated the frequency of patients meeting
the intervention criteria in hemodialysis and continuous
ambulatory peritoneal dialysis (CAPD) patients who had
participated in an earlier study [40] (Table 3). On CAPD
the proportion of patients meeting the intervention cri-
teria was slightly lower. The effect of the apo(a) size
polymorphism was directionally similar to that seen in
nephrotic patients. In 22.2% of the patients with LMW
compared to 3.3% of those with HMW apo(a) types
the indication was changed when Lp(a)-corrected LDL
cholesterol levels were used. The proportion was less
among hemodialysis patients and the effect of the apo(a)
size polymorphism was less pronounced than in nephrotic
patients and CAPD patients (Table 3).
DISCUSSION
Although the highly atherogenic Lp(a) is an LDL-like
particle it is, unfortunately, not influenced by the widely
used lipid-lowering statins [7–13]. Therefore, the LDL
cholesterol-lowering effects of statins would not be very
promising in case of a combination of mild to moderate
elevated LDL cholesterol and excessively elevated Lp(a)
levels. Since the absolute reductions in LDL cholesterol
are smaller at lower levels of LDL cholesterol [41], a non-
responder or a low-responder to treatment might be hid-
den behind extremely elevated Lp(a) concentrations. In
this case a major amount of LDL cholesterol derives from
Lp(a) and simulates an LDL cholesterol value mandatory
to be treated although the Lp(a)-corrected and therefore
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Fig. 3. Low density lipoprotein (LDL) cholesterol and lipoprotein(a)
[Lp(a)]-corrected LDL cholesterol levels in patients who showed an
LDL cholesterol level ≥100 mg/dL which was below 100 mg/dL after
correction for Lp(a)-derived LDL cholesterol. The analysis is stratified
for low-molecular-weight (LMW) and high-molecular weight (HMW)
apolipoprotein(a) [apo(a)] phenotypes and shows tremendous differ-
ences between the two phenotype groups (25.7% vs. 2.3%, P < 0.00001).
treatable LDL cholesterol is below 100 mg/dL. This situ-
ation is relatively rare in the general Caucasian popula-
tion but occurs more often in African Americans with
two- to threefold higher Lp(a) levels than Caucasians
[42], in CAPD patients [40, 43, 44], or in patients with
nephrotic syndrome [16–26]. In nephrotic patients car-
rying an LMW apo(a) phenotype we can even observe
Lp(a) levels up to 300 to 600 mg/dL which corresponds to
Lp(a)-corrected LDL cholesterol levels 135 to 270 mg/dL
lower than the uncorrected LDL cholesterol levels.
Our observation has three implications. First, if a study
aims to investigate the efficacy of the LDL cholesterol-
lowering effect of a statin, it will be more accurate to con-
sider and monitor only the amount of LDL cholesterol
which is accessible for intervention. This can have a con-
siderable influence on the results. Let us consider a not
so rarely observed nephrotic patient with an Lp(a) con-
centration of 200 mg/dL and a total LDL cholesterol of
200 mg/dL and therefore an Lp(a)-corrected LDL choles-
terol of 110 mg/dL. If in this case a statin leads to only
30 mg/dL reduction of LDL cholesterol, the effectiveness
will be either 15% or 27% depending whether total or
Lp(a)-corrected LDL cholesterol is used for calculation.
Second, guidelines from the National Kidney Founda-
tion (K/DOQI) recently classified chronic kidney disease
as coronary heart disease risk equivalent [45]. Accord-
ing to the ATP III guidelines, a coronary heart disease
risk equivalent carries a risk for a major coronary event
equal to that of established coronary heart disease (i.e.,
>20% per 10 years) [38]. In presence of coronary heart
disease or a coronary heart disease risk equivalent, the
LDL cholesterol goal is below 100 mg/dL which should
be achieved by therapeutic lifestyle changes and/or lipid-
lowering drug therapy. However, 25.6% of all nephrotic
patients with LMW apo(a) phenotypes would be clas-
sified as no longer to be in need of lipid-lowering
intervention, when Lp(a)-corrected LDL cholesterol in-
stead of total LDL cholesterol is used for therapeutic de-
cision. Since this is very rarely observed in patients with
HMW apo(a) phenotypes (2.2%), a pharmacogenetic ef-
fect caused by the apo(a) polymorphism can be assumed.
To be precise we should better call it a “pseudopharma-
cogenetic” effect since it is simulated by incorrectly mea-
sured (calculated) LDL cholesterol levels. The situation is
very similar in CAPD patients (22.2% vs. 3.3%) who have
besides nephrotic patients one of the highest pathologic
Lp(a) levels [40, 43]. It is less pronounced in hemodialy-
sis patients (15.4% vs. 9.8%) which can be explained by
the less intensive elevation of Lp(a) when compared to
CAPD patients and by the apo(a) phenotype-dependent
elevation of Lp(a) described earlier (Table 3) [36, 43, 46].
Third, clinical recommendations and guidelines are
mostly based on the results of intervention studies. These
studies when focused on cholesterol, however, based
their analysis usually on total LDL cholesterol and not
on Lp(a)-corrected LDL cholesterol levels since most
studies up to now did not use a modified Friedewald
formula. The question is whether the therapeutic goal
(LDL cholesterol <100 mg/dL) would change if Lp(a)-
corrected LDL cholesterol levels were used especially in
a group of patients with tremendously elevated Lp(a) lev-
els such as patients with nephrotic syndrome. Due to the
lack of multiple randomized controlled trials in kidney
patients, guidelines in these patients are mostly based on
the results from the general population where we usually
do not observe these high Lp(a) levels. Very soon such
studies in kidney patients will be available and will be the
basis for future guidelines. These studies have the chance
to perform the analysis of the data in both ways and to
adjust the goals accordingly if advantageous.
We do not expect that this observation has a major
impact on the general Caucasian population which has
usually not such high Lp(a) levels. This is supported
by a recent study which showed that the relative risk
for ischemic heart disease is almost the same when the
LDL cholesterol is calculated by the classical Friedewald
formula or by the modified formula which corrects for
Lp(a)-derived LDL cholesterol [47]. Nevertheless, rare
cases with markedly elevated Lp(a) levels (e.g., >150
mg/dL) might be responsible for nonresponders or
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low-responders to statins when LDL cholesterol is only
moderately elevated. In addition, our observation might
be particularly important in patients of African Ameri-
can origin who present generally with much higher Lp(a)
levels [42, 44].
Recently, Scanu and Hinman [8] investigated the in-
fluence of statins on hypercholesterolemic subjects with
high Lp(a) levels and observed in some cases an Lp(a)-
corrected LDL cholesterol decrease as low as 10 mg/dL.
The decrease of the Lp(a)-corrected LDL cholesterol
levels was proportional to the pretreatment ratio of the
Lp(a)-corrected LDL cholesterol to Lp(a) concentra-
tions. That means that the decrease of LDL cholesterol
was strongly dependent on the accessible LDL choles-
terol demonstrating that only cholesterol from LDL
cholesterol and not Lp(a) is affected by statin therapy [8].
Ongoing large trials in renal patients will provide the pos-
sibility to study such an effect easily in the setting of renal
disease. If our suggestion is confirmed by these studies,
about 25% of all renal patients with an LMW apo(a) phe-
notype would not have to undergo lipid-lowering ther-
apy by statins when the indication for the therapy is only
made by the goals of lipid-lowering. Furthermore, in cases
of nonresponders or low-responders with this constel-
lation it might not be useful to increase the dosage of
statins. Whether the pleiotropic effects of statins includ-
ing an anti-inflammatory action through a reduction of
oxidative stress, nuclear factor-jB (NF-jB) activation,
intercellular adhesion molecule-1 (ICAM-1) expression
and macrophage infiltration [48] are sufficiently ad-
vantageous in this subgroups compared to the risk of
side-effects might be answered by the same studies. Nev-
ertheless, it can already be helpful at this stage to cal-
culate the Lp(a)-corrected LDL cholesterol levels if a
particular patient does not respond sufficiently to statin
therapy. If high Lp(a) levels are indeed the cause for
a disappointing LDL cholesterol-lowering effect of a
statin, such a patient might benefit from alternative ther-
apies which were reported to lower Lp(a) levels. Those
are a treatment with the nicotinic acid analogue nicer-
itrol which showed pronounced Lp(a)-lowering effects in
chronic renal disease and hemodialysis patients [49, 50] or
a combination therapy of an extended-release niacin with
a statin [51] which might probably add the pleiotropic
effects of the latter.
Limitations of the study
Due to the repetitive K-IV motif of apo(a), a recent
study showed some evidence that Lp(a) is overestimated
in subjects with HMW apo(a) isoforms if measured by
an assay which uses antibodies directed against the K-IV
motif [52]. If our assay would indeed overestimate Lp(a)
in HMW apo(a) isoforms this would result in even lower
values of Lp(a)-derived LDL cholesterol in patients with
HMW apo(a) phenotypes and therefore an even stronger
“pseudopharmacogenetic” effect.
CONCLUSION
We show in this investigation that a considerable
amount of LDL cholesterol in patients with nephrotic
syndrome derives from Lp(a) and that this strongly de-
pends on the apo(a) polymorphism. Since the Lp(a)-
derived LDL cholesterol can not be modulated by statins,
a markedly higher frequency of patients with LMW than
with HMW apo(a) phenotypes would be classified to be
no longer in need of lipid-lowering therapy by statins
when Lp(a)-corrected LDL cholesterol instead of total
LDL cholesterol is used for therapeutic decision.
NOTE ADDED IN PROOF
Because triglyceride levels above 400 mg/dL influence
the Friedewald formula, we excluded in an additional
subanalysis 23 patients and 5 control patients with these
high triglyceride levels. Nevertheless, we observed virtu-
ally the same Lp(a)-derived LDL cholesterol and Lp(a)-
corrected LDL cholesterol levels as presented in Table
1. Furthermore, the frequency of nephrotic patients who
have to be considered for therapeutic intervention re-
mained almost the same as presented in Table 3.
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